Strength of statistical evidence for the efficacy of cancer drugs: a Bayesian reanalysis of randomized trials supporting Food and Drug Administration approval
These videos have been matched automatically. Contact us if they are not relevant.
These videos have been matched automatically. Contact us if they are not relevant.
View abstract on PubMed
Summary
This summary is machine-generated.Most new cancer drugs lack strong statistical evidence for improving overall survival (OS). Bayes factors (BFs) reveal that progression-free survival and tumor response show stronger evidence, but some approvals lack efficacy evidence altogether.
Area Of Science
- Oncology
- Biostatistics
- Drug Regulation
Background
- The Food and Drug Administration (FDA) approves novel cancer drugs based on evidence from randomized controlled trials (RCTs).
- Quantifying the statistical strength of evidence for these approvals is crucial for understanding drug efficacy.
- Bayes factors (BFs) provide a robust statistical measure to assess evidence strength.
Purpose Of The Study
- To quantify the statistical evidence strength from RCTs for novel cancer drugs approved by the FDA over the past two decades.
- To compare the strength of evidence across different endpoints, approval pathways, treatment lines, and cancer types.
Main Methods
- Data from 82 RCTs for novel cancer drugs approved between 2000-2020 were analyzed.
- Bayes factors (BFs) were calculated for overall survival (OS), progression-free survival, and tumor response.
- Bayesian fixed-effect meta-analysis was used to pool evidence for indications approved based on two RCTs.
Main Results
- Median statistical evidence was ambiguous for OS (BF=1.9) but strong for progression-free survival (BF=24,767.8) and tumor response (BF=113.9).
- Over 58% of indications lacked clear statistical evidence for OS improvement, and 9.3% lacked evidence for any endpoint improvement.
- Accelerated approvals showed weaker statistical evidence compared to non-accelerated approvals.
Conclusions
- Bayes factors offer novel insights into the statistical evidence supporting cancer drug approvals.
- A significant number of novel cancer drugs lack robust statistical evidence for improving OS, and some lack evidence for efficacy.
- Ambiguous evidence warrants transparent explanations and may necessitate postmarketing trials to reduce uncertainty.
These videos have been matched automatically. Contact us if they are not relevant.
These videos have been matched automatically. Contact us if they are not relevant.
Related Concept Videos
Cancer survival analysis focuses on quantifying and interpreting the time from a key starting point, such as diagnosis or the initiation of treatment, to a specific endpoint, such as remission or death. This analysis provides critical insights into treatment effectiveness and factors that influence patient outcomes, helping to shape clinical decisions and guide prognostic evaluations. A cornerstone of oncology research, survival analysis tackles the challenges of skewed, non-normally...
Survival analysis is a cornerstone of medical research, used to evaluate the time until an event of interest occurs, such as death, disease recurrence, or recovery. Unlike standard statistical methods, survival analysis is particularly adept at handling censored data—instances where the event has not occurred for some participants by the end of the study or remains unobserved. To address these unique challenges, specialized techniques like the Kaplan-Meier estimator, log-rank test, and...
The hazard ratio (HR) is a widely used measure in clinical trials to compare the risk of events, such as death or disease recurrence, between two groups over time. It reflects the ratio of hazard rates—the instantaneous risk of the event occurring—between a treatment group and a control group. This measure provides valuable insights into the relative effectiveness of a treatment by assessing how the risk of an event differs between the two groups.
For example, in a clinical trial...
Biopharmaceutical studies constitute a vital field aiming to enhance drug delivery methods and refine therapeutic approaches, drawing upon diverse interdisciplinary knowledge. In research methodologies, the choice between controlled and non-controlled studies significantly influences the study's reliability and accuracy.
Non-controlled studies, commonly employed for initial exploration, lack a control group, rendering them susceptible to biases and external influences. In contrast,...
The Kaplan-Meier estimator is a non-parametric method used to estimate the survival function from time-to-event data. In medical research, it is frequently employed to measure the proportion of patients surviving for a certain period after treatment. This estimator is fundamental in analyzing time-to-event data, making it indispensable in clinical trials, epidemiological studies, and reliability engineering. By estimating survival probabilities, researchers can evaluate treatment effectiveness,...
Epidemiological data primarily involves information on specific populations' occurrence, distribution, and determinants of health and diseases. This data is crucial for understanding disease patterns and impacts, aiding public health decision-making and disease prevention strategies. The analysis of epidemiological data employs various statistical methods to interpret health-related data effectively. Here are some commonly used methods:
Descriptive Statistics: These provide basic...